“INVESTIGATORY” TRANSPLANTS Helen Heslop Roy Jones.

Slides:



Advertisements
Similar presentations
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Advertisements

Copyright © Healthcare Quality Quest, Proposed standards for a national clinical audit — How we got involved and what we have learned.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
How to Write a Research Proposal Detroit Medical Center Nursing Research Council.
Formulating The Method
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
Capturing and Reporting Adverse Events in Clinical Research
Evidenced Based Practice; Systematic Reviews; Critiquing Research
How does the process work? Submissions in 2007 (n=13,043) Perspectives.
Writing a Research Protocol Michael Aronica MD Program Director Internal Medicine-Pediatrics.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Module 2 Sealy Center on Aging What kinds of scholarly products can I produce?
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Efficiency of stroke clinical trials with ordinal outcomes: a simulation study UPC, Julio 2010 BASEL, October 2011 Juan Vicente Torres Supervisors: Dr.
Research-driven data standards CIMI 11 th April 2013.
The IRB's Position on Quality Projects vs. Research R. Peter Iafrate, Pharm.D. Chairman, Health Center IRB University of Florida.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
How to Write a Scientific Paper Hann-Chorng Kuo Department of Urology Buddhist Tzu Chi General Hospital.
Pilot Study Design Issues
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
Introduction to Basic Science Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.
Musical Therapy for the Agitated Alzheimer's Patient By Stephanie Markarian.
Research Design. Research is based on Scientific Method Propose a hypothesis that is testable Objective observations are collected Results are analyzed.
Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2012.
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
Lecture 8 Research Proposal.  Find out what is the required format of research proposal  Research Proposal is a solid and convincing framework of a.
Clinical Trial Designs An Overview. Identify: condition(s) of interest, intended population, planned treatment protocols Recruitment of volunteers: volunteers.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Concept Sheet Development: Developing the Question Kara Wools-Kaloustian M.D. M.S.
Tips for Researchers on Completing the Data Analysis Section of the IRB Application Don Allensworth-Davies, MSc Statistical Manager, Data Coordinating.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
Center-specific Outcomes 2010 Current Status Future Directions SUM07_1.ppt.
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.
EXPERIMENTAL EPIDEMIOLOGY
1 Clinical trials with stem cells Bernard Lo, M.D. February 12, 2009.
Critical Appraisal (CA) I Prepared by Dr. Hoda Abd El Azim.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Biostatistics Basics: Part I Leroy R. Thacker, PhD Associate Professor Schools of Nursing and Medicine.
First Author: Ráduly Kinga Author: Ráduly Orsolya Coordinators: Dr. Zaharia Kézdi Iringo, Dr. Nina Sincu.
Onsite Quarterly Meeting SIPP PIPs June 13, 2012 Presenter: Christy Hormann, LMSW, CPHQ Project Leader-PIP Team.
C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.
Strengthening Research Capabilities Professor John B. Kaneene DVM, MPH, PhD, FAES, FAVES Center for Comparative Epidemiology Michigan State University.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia? Eur J Haematol Feb. R2 이 홍 주.
Ashkan Emadi 1, Steven D. Gore Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, United States Blood Reviews 24 (2010)
9 Procedure for Conducting an Experiment.
PUBLICATION OF ARTICLES IN SCIENTIFIC JOURNALS:
CLINICAL PROTOCOL DEVELOPMENT
How to Write a Research Proposal
Criteria For Critiquing A Research Report
The Role of Statistics in Clinical Trials
Clinical Study Results Publication
SPECIMEN SONOGRAM - Procedure
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
S1316 analysis details Garnet Anderson Katie Arnold
Treating Transplant-Ineligible Patients With Multiple Myeloma
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Changes to HCC Criteria for Auto Approval
BU Career Development Grant Writing Course- Session 3, Approach
Evidence Based Practice
Stat4Onco Annual Symposium Zhenming Shun April 27, 2019
Introduction to Basic Research Methods
SYNOPSIS OF THE PROTOCOL
Presentation transcript:

“INVESTIGATORY” TRANSPLANTS Helen Heslop Roy Jones

Pivotal Question Does participation in early-phase, therapeutically-oriented clinical trials have independent prognostic significance for OUTCOME? Motivation: avoid punishing centers conducting high-risk research if outcomes are inferior as a result

Examples of Trials “Near Myeloablative” preparative regimen for myeloma patients Minimal intensity preparation for high risk tumors Transplant for “new” diseases Second allotransplants Strategies to reduce risk of relapse in high risk patients

Hypothesis Participation in an early-phase therapeutically-directed clinical trial is an independently negative prognostic factor –Patients participating in these studies are at higher risk for adverse outcomes than those receiving standard of care treatments –Already-collected patient variables do not adequately describe this risk

Operational Questions How do we uniformly identify these trials and patients participating in them? How do we acquire and use the information?

Proposal Identify research trials and later identify patients participating in them. Identify research participation as a single data collection element reportable to the SCTOD (dichotomous variable) Analyze independent effect on outcome using established statistical techniques, likely in a pilot fashion.

Identification of Research Trials Simple protocol-specific questionnaire to be filled out and scored by centers. Y/N reply to a provisional data element included in FormsNet based on a given patient’s research study participation –Intent to treat Analysis by SCTOD staff Formal adoption as a data element only if hypothesis is accepted.

Content of Trial Questionnaire IRB approval: Y Peer-reviewed, published, reproducible: N Correct answer required Therapeutic intent: Y Use of non-standard cell products: Y Toxicity mitigation of high-risk therapy: Y Older or high-comorbidity patients: Y One of four must be yes

Questions or Comments?

Screening Questions Is the treatment protocol IRB-approved? Has the protocol treatment been published in the peer-reviewed literature in sufficient detail to be reproduced? Answer to Q1 must be YES Answer to Q2 must be NO

Screening Questions Is the protocol designed to treat malignancy, genetic disease, or aplastic anemia? Does the protocol propose the use of unrelated cell products outside of the specifications in Q#2? Is the protocol designed to mitigate toxicity where the estimate of fatal toxicity for the protocol exceeds 30%? Is the protocol designed to enroll older patients (allos >60, autos >65) or patients with high comorbidity scores (HCT-CI>2)? At least one must be YES